4xz2: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Human platelet phosphofructokinase in an R-state in complex with ADP and F6P, crystal form I== | ==Human platelet phosphofructokinase in an R-state in complex with ADP and F6P, crystal form I== | ||
<StructureSection load='4xz2' size='340' side='right' caption='[[4xz2]], [[Resolution|resolution]] 2.67Å' scene=''> | <StructureSection load='4xz2' size='340' side='right'caption='[[4xz2]], [[Resolution|resolution]] 2.67Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4xz2]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4XZ2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4XZ2 FirstGlance]. <br> | <table><tr><td colspan='2'>[[4xz2]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4XZ2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4XZ2 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ADP:ADENOSINE-5-DIPHOSPHATE'>ADP</scene>, <scene name='pdbligand=F6P:FRUCTOSE-6-PHOSPHATE'>F6P</scene>, <scene name='pdbligand=FBP:BETA-FRUCTOSE-1,6-DIPHOSPHATE'>FBP</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ADP:ADENOSINE-5-DIPHOSPHATE'>ADP</scene>, <scene name='pdbligand=F6P:FRUCTOSE-6-PHOSPHATE'>F6P</scene>, <scene name='pdbligand=FBP:BETA-FRUCTOSE-1,6-DIPHOSPHATE'>FBP</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4wlo|4wlo]], [[4u1r|4u1r]], [[4rh3|4rh3]], [[4omt|4omt]], [[3opy|3opy]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4wlo|4wlo]], [[4u1r|4u1r]], [[4rh3|4rh3]], [[4omt|4omt]], [[3opy|3opy]]</td></tr> | ||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">PFKP, PFKF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | |||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/6-phosphofructokinase 6-phosphofructokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.11 2.7.1.11] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/6-phosphofructokinase 6-phosphofructokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.11 2.7.1.11] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4xz2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4xz2 OCA], [http://pdbe.org/4xz2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4xz2 RCSB], [http://www.ebi.ac.uk/pdbsum/4xz2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4xz2 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4xz2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4xz2 OCA], [http://pdbe.org/4xz2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4xz2 RCSB], [http://www.ebi.ac.uk/pdbsum/4xz2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4xz2 ProSAT]</span></td></tr> | ||
| Line 20: | Line 21: | ||
</div> | </div> | ||
<div class="pdbe-citations 4xz2" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 4xz2" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Phosphofructokinase (PFK)|Phosphofructokinase (PFK)]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 25: | Line 29: | ||
</StructureSection> | </StructureSection> | ||
[[Category: 6-phosphofructokinase]] | [[Category: 6-phosphofructokinase]] | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | |||
[[Category: Kloos, M]] | [[Category: Kloos, M]] | ||
[[Category: Strater, N]] | [[Category: Strater, N]] | ||
Revision as of 03:12, 6 June 2019
Human platelet phosphofructokinase in an R-state in complex with ADP and F6P, crystal form IHuman platelet phosphofructokinase in an R-state in complex with ADP and F6P, crystal form I
Structural highlights
Function[PFKAP_HUMAN] Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis. Publication Abstract from PubMedPhosphofructokinase-1 (Pfk) acts as the main control point of flux through glycolysis. It is involved in complex allosteric regulation and Pfk mutations have been linked to cancer development. Whereas the 3D structure and structural basis of allosteric regulation of prokaryotic Pfk has been studied in great detail, our knowledge about the molecular basis of the allosteric behaviour of the more complex mammalian Pfk is still very limited. To characterize the structural basis of allosteric regulation, the subunit interfaces and the functional consequences of modifications in Tarui's disease and cancer, we analysed the physiological homotetramer of human platelet Pfk at up to 2.67 A resolution in two crystal forms. The crystallized enzyme is permanently activated by a deletion of the 22 C-terminal residues. Complex structures with ADP and fructose-6-phosphate (F6P) and with ATP suggest a role of three aspartates in the deprotonation of the OH-nucleophile of F6P and in the co-ordination of the catalytic magnesium ion. Changes at the dimer interface, including an asymmetry observed in both crystal forms, are the primary mechanism of allosteric regulation of Pfk by influencing the F6P-binding site. Whereas the nature of this conformational switch appears to be largely conserved in bacterial, yeast and mammalian Pfk, initiation of these changes differs significantly in eukaryotic Pfk. Crystal structure of human platelet phosphofructokinase-1 locked in an activated conformation.,Kloos M, Bruser A, Kirchberger J, Schoneberg T, Strater N Biochem J. 2015 Aug 1;469(3):421-32. doi: 10.1042/BJ20150251. Epub 2015 Jun 11. PMID:26205495[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||||||